Australia's Optiscan Imaging gains on ethical clearance for breast cancer study
** Shares of Optiscan Imaging OIL.AX rise 12.82% to
A$0.22, on track for their best day since June 24, if gains hold
** The imaging technologies maker receives ethical clearance
for breast cancer study
** Co says the study will assess the clinical workflow and
real-time imaging capability of its recently unveiled InVue
precision surgery imaging platform in breast cancer
** Stock has doubled gains this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((sherin.sunny@thomsonreuters.com))
Recent news on Optiscan Imaging
See all newsBrief: Optiscan Imaging Lodges US FDA Dossier For Inspecta For Veterinary Market
Australia's Optiscan Imaging rises on deal with Australian Clinical Labs
Brief: Optiscan Imaging Enters Strategic Collaboration With Australian Clinical Labs
Brief: Optiscan Imaging Launches A$17.75M Entitlement Offer
Australia's Optiscan Imaging rises on collaboration with US-based firm